CD147、基质金属蛋白酶和转化生长因子β1在乳腺癌中的表达与肿瘤转移和预后及其相互间的关系

Expression of CD147, matrix metalloproteinases and transforming growth factor β1 in breast cancer

目的探讨CD147和基质金属蛋白酶（MMP）-2和MMP-9与转化生长因子（TGF）β1及其Ⅰ型受体（TGFβRⅠ）在乳腺癌组织中的表达与肿瘤转移和预后及其相互间的关系。方法建立组织芯片平台，应用免疫组织化学SP法检测160例乳腺癌组织CD147、MMP-2、MMP-9、TGFβ1和TGFβRⅠ蛋白的表达情况，并进行了8～64个月随访。结果160例乳腺癌中CD147、MMP-2、MMP-9、TGFIM和TGFβRⅠ阳性率分别为87．5％（140例）、96．9％（155例）、95．0％（152例）、73．7％（118例）和60．6％（97例）；CD147的表达与乳腺癌腋淋巴结受累、TNM分期和HER2过表达均呈正相关（P〈0．01，P〈0．05和P〈0．01），与孕激素受体表达呈负相关（P〈0．05）；CD147蛋白阳性患者（55．9个月）无复发生存期显著低于阴性患者（46．1个月，P=0．023）；CD147与MMP-2、MMP-9蛋白的表达均呈显著正相关（r=0．728和r=0．399，均P〈0．01）；CD147蛋白表达与TGFβ1和TGFβRⅠ表达均呈显著正相关（r=0．223，P〈0．01和r=0．191，P〈0．05）。结论乳腺癌组织中CD147表达状况与肿瘤侵袭转移和患者预后有密切关系；CD147的表达与MMP-2、MMP-9、TGFβ1和TGFβRⅠ表达状况关系密切。

Objective To investigate the expression of CD147, matrix metalloproteinase （MMP）- 2, MMP-9, Transforming growth factor （TGFβ1） and TGFβR Ⅰ proteins and their relationships to breast cancer. Methods The expression of CD147, MMP-2, MMP-9, TGFβ1 and TGFβR Ⅰ proteins was examined on tissue chips containing 160 cases of breast carcinomas by S-P immunohistochemical method. Results The positive rates of CD147, MMP-2, MMP-9, TGFβ1 and TGFβR Ⅰ proteins were 87.5% （ 140/160 ） , 96. 9% （ 155/160 ） , 95.0% （ 152/160 ） , 73.7% （ 118/160 ） and 60. 6% （ 97/160 ） , respectively. The expression of CD147 was positively correlated with axillary lymph node metastasis, TNM staging and HER2 over expression （ P 〈 0. 01, P 〈 0. 05 and P 〈 0.01, respectively ） , and inversely correlated with PR expression （P 〈0. 05）. The patients＇ relapse-free survival was shorter in TGFβ1-positive group than in TGFβ1 negative group （ P 〈 0. 05 ）. Both the expression of MMP-2 and MMP-9 were positively correlated with CD147 expression; and both the expression of TGFβ1 and TGFβR Ⅰ were positively correlated with CD147 expression （P 〈0.01 and P 〈0. 05, respectively）. Conclusion The expression of CD147 is considered closely correlated with tumor invasion, metastasis and prognosis in breast cancer, and has also a close correlation with MMP-2, MMP-9, TGFβ1 and TGFβR I expression.